{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Frequency of response to entinostat per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and/or assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, stratified by study part and dose","groups":[{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 3 mg/m2","id":"OG000","title":"Stratum 1 With 3 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 4 mg/m2","id":"OG001","title":"Stratum 1 With 4 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors without bone marrow involvement, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at the RP2D (4 mg/m2)","id":"OG002","title":"PK Part With 4 mg/m²"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All eligible enrolled patients.","reportingStatus":"POSTED","timeFrame":"Up to 4 years 9 months","title":"Antitumor Activity of Entinostat","type":"SECONDARY","unitOfMeasure":"Participants"}